Analysis
AI & Data
Beyond HLA-DR intensity: the overlooked myeloid phenotypes in rheumatoid arthritis
Spectral immunophenotyping finds altered co-stimulatory and adhesion-marker patterns, and a small HLA-DR+CD15+CD16+ compartment. Phenotype may suggest a function, but does not demonstrate it.
When immune activation is suspected, it is tempting to search for a global rise in HLA-DR. But antigen-presenting cells can change how they interact with other cells without a simple increase in that marker. A spectral-cytometry study of rheumatoid arthritis offers a useful example of why the identity of the subset and the combination of markers matter more than a single global fluorescence readout.
Geier and colleagues profiled circulating HLA-DR-positive cells from patients with rheumatoid arthritis and healthy controls, including conventional dendritic and monocyte subsets. Their central descriptive result was not a uniform HLA-DR increase. Instead, several subsets differed in co-stimulatory, adhesion and migratory markers, while a small HLA-DR+CD15+CD16+ population emerged as an unusual phenotype of interest.

The markers that carried the contrast
CD1c-positive DC2 showed higher fluorescence for CD86 and CD275 (ICOS-L) in patients than controls, with reported p-values of 0.0184 and 0.0046. The authors also observed higher CD56 and CCR7 in DC2, and differences involving CD15 in dendritic and monocyte compartments. They did not find a generalized elevation of HLA-DR in monocytes or dendritic cells; HLA-DR was elevated in B cells. These are subset-specific associations rather than evidence that all myeloid antigen presentation was higher.
The study also identified an HLA-DR+CD15+CD16+ population associated with inflammatory indicators. It accounted for a reported mean of approximately 1.3% of the HLA-DR-positive antigen-presenting compartment, with substantial between-sample dispersion (SD 2.85%). It expressed CD83 and CD275 and showed some CD303 positivity, but its comparatively weak CD123 distinguished it from typical plasmacytoid dendritic-cell patterns in this dataset.
What should the gate be called?
The phenotype overlaps with granulocytic and dendritic-associated programs. The investigators discuss possible relationships to low-density granulocytes or hybrid populations. These are biologically interesting interpretations, not definitive lineage assignments. Neither a t-SNE neighborhood nor co-expression of HLA-DR and CD15 proves developmental origin or antigen presentation. Functional antigen-processing and T-cell activation assays would be required to substantiate the proposed mechanism.
For a laboratory reusing this approach, sample composition and acquisition gates are as important as the marker list. The original study examined peripheral blood, focused on patients with marked disease activity and used HLA-DR positivity as a broad screening criterion. A receiving laboratory must test low-density granulocyte contamination, viability, doublet exclusion, population recovery and the effects of its own specimen preparation before accepting a rare cluster as a biological entity.
A defensible clinical message
The findings suggest altered immune-cell activation phenotypes in the studied rheumatoid-arthritis samples. They do not establish a diagnostic test, a specific pathogenic cell lineage or treatment-response prediction. The authors note cohort-size and clinical-data limitations, including unavailable clinical disease activity scores. Claims about antigen presentation should therefore remain conditional, even when co-stimulatory-marker changes are reproducible.
Daily Learning Pill: HLA-DR-positive means a measurable phenotype, not proof that the event is functionally presenting antigen. Separate phenotypic description, lineage inference and direct functional evidence in every report.
Source and scope: Geier C et al., Frontiers in Immunology (9 July 2025), DOI 10.3389/fimmu.2025.1596609. CFCM analytical interpretation and original conceptual schematic; not a clinical validation or a reproduction of journal artwork.